In addition, preclinical evidence highlights a potential link between increased C-Myc activity and acquired resistance to standard-of-care chemotherapeutics, which might serve as a potential explanation why SCLC patients with a higher C-Myc abundance face a dismal overall prognosis [12, 54]. Here, MYC is linked to small cell lung carcinoma.